

Jose-Marie El-Amm, M.D.

Office Address:

4160 John R. Suite 908
Detroit, MI 48201

Telephone: 313.745.7145

EDUCATION:

1990	French Baccalaureate <i>Beirut, Lebanon</i>
1990	Baccalaureate II-Experimental Sciences <i>Beirut, Lebanon</i>
1990-1993	Bachelor Degree in Biology <i>American University of Beirut Beirut, Lebanon</i>
1993-1997	Medical Doctor Degree <i>American University of Beirut Beirut, Lebanon</i>

HOSPITAL TRAINING:

1997-2000	Internal Medicine Residency <i>Wayne State University Detroit, MI</i>
2000-2002	Fellowship in Nephrology <i>Wayne State University Detroit, MI</i>
2002-2003	Fellowship in Transplantation <i>Henry Ford Hospital Detroit, MI</i>

HOSPITAL AND PROFESSIONAL APPOINTMENTS:

2003 - Present	Transplant Nephrologist, Harper University Hospital Medical Director of Renal Transplant Program Assistant Professor of Medicine Residency Coordinator, Division of Nephrology Wayne State University
----------------	--

PROFESSIONAL SOCIETIES:

American Society of Nephrology
American Society of Transplantation

LICENSES AND CERTIFICATIONS:

American Board of Internal Medicine; 2001 (Certification Number: 202025)
American Board of Nephrology; 2003 (Certification Number: 202025)
Licensure: Michigan
ACLS/BLS Certified; 2006

HONORS AND AWARDS:

1990	Rank #7 in the World - International French Baccalaureate Examination
1990-1993	Dean's honor list throughout undergraduate studies
1990-1994	Dean's honor list throughout medical school
1997	<i>Alpha Omega Alpha</i> member-Honor Society
1997	"Intern of the Year", Department of Internal Medicine <i>Wayne State University</i>
1997-2000	In-service exam score for 3 years in a row: 99%
2000	1 st Place Winner "Best Research"- <i>Wayne State University</i>
2000	" <i>Resident of the Year</i> "- Department of Internal Medicine- <i>Wayne State University</i>
2001	American board certification in Internal Medicine Score: 10/10
2002	" <i>Fellow of the Year</i> ", Department of Internal Medicine <i>Wayne State University</i>
2003	American Board of Nephrology Score: 10/10

MANUSCRIPT REVIEWER

Advances in Chronic Kidney Diseases: "Infectious complications in renal transplant recipients", R. Parasuraman et al.

Clinical Transplantation: "The efficacy, Safety and Feasibility of Long-Term Two-Hour Cyclosporine Level Monitoring in African American Patients", L Zsom et al.

COMMITTEES:

Compliance committee; Wayne State University

Paired Donor Consortium Committee

Residency Operation Committee; Wayne State University

PRINCIPAL INVESTIGATOR:

1. Living Donor Kidney Exchange Program
2. C2 vs. C0 monitoring in African American Recipients: Randomized Control Trial
3. Renal function with calcineurin inhibitor versus sirolimus based immunosuppression and early corticosteroid withdrawal in kidney transplant recipients: C0-PI with Scott Gruber, MD.

SERVICE:

Patient Care:

Inpatient rounds on Chronic Kidney Disease service 3 months per year
Outpatient clinic; Pre and Post-transplant clinic 9 months per year

Professional consultation:

3 Half days pre-transplant consultation for the transplant surgery team

Other professionally related service:

Detroit Festival of Arts-Physician Group-Community Outreach-2001
Primary Care Week-Wayne State University-2001

TEACHING:

Years at Wayne: Since July 2003

Years at other colleges/universities: None

Essays/Theses/Dissertations directed: None

Courses at Wayne State School of Medicine:

Renal Pathophysiology Seminars for second year medical students, 2004, 2005, 2006, 2007(11.5 hrs)

Chronic Kidney Disease lecture for second year medical students, 2007
(2 hrs)

Clinical training sessions:

Transplant clinic, 3 nephrology fellows, 3 half days per week, 2006

Inpatient nephrology service, 1 fellow + 4 residents, 3 months per year, 2006

GRANT SUPPORT:

Research Grant: *MTSF Fund (Medical Staff Trust Fund)*

1/2/2002-4/30/03, "Prevalence and Clinical Significance of hypercoagulability in ESRD"; \$24,800; James Sondheimer, MD Principle Investigator, *funding approved 9/7/01.*

Role: Data collection, interpretation, and manuscript writing: %effort=20%.

ORIGINAL OBSERVATIONS IN REFEREED JOURNALS:

1. Haririan A, Morawski K, Sillix DH, *El-Amm JM*, Garnick J, West MS, Granger DK, Migdal SD, Gruber SA. Induction therapy with Basiliximab versus Thymoglobulin in African-American kidney transplant recipients. *Transplantation* 27;79(6):716-721, 2005.
2. Gruber SA, Garnick J, Morawski K, Sillix D, West M, Granger D, *El-Amm J.M.*, Alangaden G, Chandrasekar P, Haririan A. Cytomegalovirus Prophylaxis with Valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. *Clin Transplant* 19(2):273-8, 2005.
3. Gruber S, West M, Sillix D, *El-Amm JM*, Garnick J, Morawski K, Haririan A. Preliminary Results with steroid-avoidance immunosuppression in African-American renal allograft recipients. *Surgery* 138(4):772-9, 2005.
4. Haririan A, Fagoaga O, Daneshvar H, Morawski K, Sillix DH, *El-Amm JM*, West MS, Garnick J, Migdal SM, Gruber SA, Nehlsen-Cannerella S. Predictive value of HLA epitope matching using HLAMatchmaker for graft outcomes in a predominantly African-American renal transplant cohort. *Clin Transplant*, 2006:20:226-233.
5. Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, *El-Amm JM*, West MS, Sillix DH, Chandrasekar PH, Haririan A. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. *Clin Transplant*, 2006:20(4):401-409.
6. Haririan A, Sillix DH, Morawski K, *El-Amm JM*, Garnick J, Doshi M, West MS, Gruber SA. Experience with early steroid withdrawal in African-American renal transplant recipients. *Amer J Transplant*. 2006:6(10):2396-2402.
7. *El-Amm JM*, Doshi M, Singh A, Migdal S, Morawski K, Sternbauer D, Cincotta E, West M, Losanoff J, Gruber S. Preliminary experience with cinacalcet use in persistent

secondary hyperparathyroidism after kidney transplantation. *Transplantation*, 2007;83(5).

8. Haririan A, Sillix D, Morawski K, ***El-Amm JM***, Doshi M, West M, Gruber S. Sirolimus based immunosuppressive regimen reduces the risk of CMV in renal allograft recipients. ***Clin Transplant***, in Press.

REVIEW ARTICLES

1. ***El-Amm JM***, Haririan A, Crook E. The effects of blood pressure and lipid control on kidney allograft outcome. ***Am J Cardiovasc Drugs***. 2006;6 (1):1-7.

CASE REPORTS:

1. Wadei H, Alangaden GJ, Sillix DH, ***El-Amm JM***, Gruber SA, West M, Granger DK, Garnick J, Chandrasekar P, Migdal SD, Haririan A. West Nile Encephalitis: An emerging disease in renal transplant patients. ***Clin transplant*** 18: 753-758, 2004.
2. Wadei H, Gruber SA, ***El-Amm JM***, Garnick J, West MS, Granger DK, Sillix DH, Migdal SD, Haririan A. Sirolimus induced angioedema. ***Am J Transplant*** 4(6):1002-5, 2004.

PUBLISHED ABSTRACTS

1. ***El-Amm J.M.***, El-Rayes B., Andersen J., Rossi N. Broad Array of Coagulation Defects in Patients with membranous nephropathy and minimal change disease. ***J Am Soc Nephrol*** 13: 676A, 2002.
2. ***El-Amm J.M.***, El-Rayes B., Andersen J., Rossi N. Vascular access thrombosis and hypercoagulable states. ***J Am Soc Nephrol*** 13:712A, 2002.
3. El-Rayes B.,***El- Amm J.M.***, Sondheimer J., Andersen J. Prevalence of hypercoagulable conditions in dialysis patients; ***Proceedings of the Am Soc Hematology***, 12A,2002.
4. ***El-Amm J.M.***, Parasuraman R., Yee J., Venkat K.K. Rapamycin substitution for calcineurin inhibitors in chronic allograft nephropathy; ***Amer J Transplant*** 5(suppl3) A235,2003.
5. Parasuraman R., Karthikeyan V., ***El-Amm J.M.***, Venkat K.K. Clinical significance of C4d stain in renal allograft biopsies of recipients presenting with thrombotic microangiopathy. ***J Am Soc Nephrol*** 14: 431A, 2003.
6. Haririan A, Morawski K , Sillix D, ***El-Amm JM***, Garnick J , Granger D , West M, Migdal S, Gruber S. Experience with sirolimus vs. tacrolimus based regimens in African-American renal transplant recipients with delayed graft function. ***J Am Soc Nephrol*** 15: A295, 2003.

7. Haririan A, Morawski K , Sillix D, ***El-Amm JM***, Garnick J , Granger D , West M, Migdal S, Gruber S .The results of Thymoglobulin (ATG) vs. Basiliximab (BSX) induction in African-American (AA) renal allograft recipients (RAR). ***J Am Soc Nephrol*** 15: A296, 2003.
8. Haririan A., Gruber S., Daneshvar H., Morawski K., ***El-Amm J.M.***, Granger D., West M., Sillix D., Fagoaga O., Nehlsen-Cannarella S.Is epitope (Epi) matching a better predictor of short-term graft outcomes than HLA matching (M)? ***Amer J Transplant*** 4 (suppl 8): 473, 2004.
9. Alangaden GJ, Thyagarajan R, Haririan A, Morawski K, Gruber SA, Garnick J, ***El-Amm JM***, West MS, Granger DK, Sillix D, Chandrasekar PH. Changing epidemiology of infections in renal transplant recipients: impact of current antimicrobial prophylaxis and immunosuppressive regimens. ***IDSA meeting***, 2004.
10. Gruber S, Morawski K, West M, Sillix D, ***El-Amm JM***, Garnick J, Haririan A. Steroid-avoidance immunosuppression in African-American renal allograft recipients. ***Amer J Transplant*** 5 (suppl 11): 463-64, 2005.
11. Haririan A, Sillix D, Morawski K, ***El-Amm JM***, West M, Garnick J, Migdal S, Gruber S. The Effect of hepatitis C virus (HCV) seropositivity on patient and graft survival and post-transplant diabetes after kidney transplantation. ***Amer J Transplant*** 5 (suppl 11): 301, 2005.
12. Haririan A, R Thyagarajan R, K Morawski K, Sillix D, ***El-Amm JM***, Garnick J, West M, Gruber S, Chandrasekar P, Alangaden G. Infectious complications after kidney transplantation; risk factors and impact on graft survival. ***Amer J Transplant*** 5 (suppl 11): 354, 2005.
13. Haririan A, Motorwala S, Gruber S, Morawski K, ***El-Amm JM***, Garnick J, West M, Migdal S, Sillix D. The effect of thiazolidinediones on graft outcomes in diabetic kidney transplant recipients. ***Amer J Transplant*** 5 (suppl 11): 317, 2005.
14. Pasupulati R, Sillix D, Gruber S, Morawski K, ***El-Amm JM***, West M, Migdal S, Haririan A. The barriers to live kidney donation in an urban setting. ***J Am Soc Nephrol*** 16, 696A, 2005.
15. ***El-Amm JM***, Nayak V, Sillix D, Gruber S, West M, Garnick J, Morawski K, Wheeler D, Migdal S, Haririan A. Post-transplant glomerulonephritis in hepatitis C positive kidney transplant recipients. ***J Am Soc Nephrol*** 16, 707A, 2005.
16. Gruber S, Morawski K, West M, Sillix D, ***El-Amm JM***, Haririan A. Steroid avoidance immunosuppression in African-Americans renal allograft recipients with multiple other high-risk factors. ***J Surg Res*** 130: 319, 2006.
17. ***El-Amm JM***, Sillix D, Doshi M, Morawski K, West M, Migdal S, Sternbauer D, Gruber S. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. ***Amer J Transplant*** 6 (suppl 12): 357, 2006.

18. Sternbauer D, Spezia G, Bal R, Obeid A, Sillix D, Doshi M, Morawski K, West M, Gruber S, Cincotta E, *El-Amm JM*. Use of Blisterpacks to improve compliance in renal allograft recipients. *Amer J Transplant* 6 (suppl 12): 825, 2006.
19. Ilioska D, Gruber S, Morawski K, Sillix D, *EL-Amm JM*, Migdal S, West M, Doshi M. Short-term medical complications following live kidney donation in a predominantly African-American cohort. *Amer J Transplant* 6 (suppl 12): 396, 2006.
20. Haririan A, Sillix D, Morawski K, *El-Amm JM*, Doshi M, West M, Gruber S. Experience with early steroid withdrawal in african american renal transplant recipients. *Amer J Transplant* 6 (suppl 12): 503, 2006.
21. Haririan A, Sillix D, Morawski K, *El-Amm JM*, Doshi M, West M, Gruber S. Sirolimus based immunosuppressive regimen reduces the risk of CMV in renal allograft recipients. *Amer J Transplant* 6 (suppl 12): 591, 2006.
22. Zeng X, *El-Amm JM*, West MS, Doshi MD, Losanoff JE, Morawski K, Cincotta E, Gruber SA. Intermediate-term outcome in African-American renal allograft recipients with early steroid withdrawal and surveillance biopsies. Central surgical association 2006.
23. Gruber SA, Morawski K, West MS, Losanoff JE, Cincotta E, Doshi MD, *El-Amm JM*. Intermediate-term outcome in African-American renal allograft recipients with early steroid withdrawal. Association for Academic Surgery/Society of University Surgeons 2006.
24. Doshi M, *El-Amm JM*, Gruber S, Sillix D, West M, Morawski K, Chandrasekar P, Alangaden G. Current epidemiology of symptomatic urinary tract infections in renal transplant recipients: emergence of enterococcus as a significant uropathogen. 44th Annual Meeting of the Infectious Diseases Society of America, Toronto. Abstract # 1022, 2006.
25. *El-Amm JM*, Doshi M, Morawski K, Gruber SA. Preliminary experience with sensipar(r) (cinacalcet hcl) use in persistent secondary hyper-parathyroidism after kidney transplantation. *Transplantation* (1 Suppl 2):357-8, 2006.
26. *El-Amm JM*, Gruber S, Sternbauer D, Doshi M, Singh A, Migdal S, Morawski K, Cincotta E, West M, Losanoff J, Haririan A. Impact of late conversion from C0 to C2 monitoring on cyclosporin A dosing and graft functional outcome in African American renal allograft recipients. ATC 2007
27. Gruber S, West M, Doshi M, Singh A, Morawski K, Cincotta E, Losanoff J, *El-Amm JM*. Early steroid withdrawal in African-American renal allograft recipients with multiple high-risk factors. ATC 2007

28. Doshi M, **El-Amm JM**, Singh A, Gruber S, West M, Losanoff J, Migdal S, Morawski K, Chandrasekar P, Alangaden G. Symptomatic urinary tract infections in renal transplant recipients: risk factors and current epidemiology. ATC 2007
29. Brown K, Doshi M, **El-Amm JM**, Singh A, Losanoff J, West M, Gruber S. Intermediate-term outcomes of hepatitis C deceased-donor renal allograft recipients. American College of Surgery meeting, 2007.

PRESENTATIONS:

1. Ascites in Sarcoidosis; *American College of Physicians*, Traverse city, MI, 1998.
2. Sirolimus switch in chronic allograft nephropathy; national fellows' conference Houston, Texas, 2002.
3. **Prevalence of hypercholesterolemia and predictors of total cholesterol levels in predominantly African-American renal allograft recipients. ACCP 2005 presented by J Clemente.**
4. **Pancreas transplantation in type I diabetics; is there a survival benefit? Endocrinology Grand Rounds, WSU, 2005.**
5. **Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. World Transplant Congress, Boston, 2006.**